Vaxil Bio Ltd. (TSXV:VXL)

Vaxil Bio Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.67	0.45	0.94	1.51	2.24
Cash & Short-Term Investments	0.67	0.45	0.94	1.51	2.24
Cash Growth	49.78%	-52.24%	-37.88%	-32.62%	48.41%
Accounts Receivable	0.01	0.02	0.04	0.03	0.04
Other Receivables	-	0.27	-	-	-
Total Trade Receivables	0.01	0.29	0.04	0.03	0.04
Total Current Assets	0.69	0.73	0.98	1.54	2.28
Net Property, Plant & Equipment	-	-	-	-	0
Long-Term Investments	0.69	-	-	-	-
Total Assets	1.37	0.73	0.98	1.54	2.29
Accounts Payable	0.01	0.02	0.09	0.41	0.59
Total Current Liabilities	0.01	0.02	0.09	0.41	0.59
Total Liabilities	0.01	0.02	0.09	0.41	0.59
Common Stock	16.13	16.07	16.07	16.07	16.07
Additional Paid-in Capital	4.33	4.26	4.26	4.24	4.22
Accumulated Other Comprehensive Income	-0.08	-0.08	-0.08	-0.07	-0.07
Retained Earnings	-19.01	-19.54	-19.36	-19.1	-18.52
Shareholders' Equity	1.37	0.72	0.89	1.14	1.7
Total Liabilities & Equity	1.37	0.73	0.98	1.54	2.29
Net Cash (Debt)	0.67	0.45	0.94	1.51	2.24
Net Cash Growth	49.78%	-52.24%	-37.88%	-32.62%	49.30%
Net Cash Per Share	0.24	0.16	0.34	0.55	0.82
Book Value	1.37	0.72	0.89	1.14	1.7
Book Value Per Share	0.48	0.26	0.33	0.41	0.62
Tangible Book Value	1.37	0.72	0.89	1.14	1.7
Tangible Book Value Per Share	0.48	0.26	0.33	0.41	0.62

Updated May 1, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.